INCY (Incyte) Cyclically Adjusted Revenue per Share: $16.83 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INCY Incyte Corp INCY
87 GF Score
Price $119.52
GF Value $105.33
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Incyte Cyclically Adjusted Revenue per Share?

Incyte INCY -2.96% 87 Cyclically Adjusted Revenue per Share is $16.83 as of Jun. 2026. GuruFocus rates INCY with a GF Score™ of 87/100 and a GF Value™ of $105.33 (Modestly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Incyte's adjusted revenue per share for the three months ended in Jun. 2026 was $8.040. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $16.83 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Incyte's average Cyclically Adjusted Revenue Growth Rate was 19.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 17.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 20.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 26.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Incyte was 36.80% per year. The lowest was -26.20% per year. And the median was 21.00% per year.

As of today (2026-08-01), Incyte's current stock price is $119.52. Incyte's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $16.83. Incyte's Cyclically Adjusted PS Ratio of today is 7.10.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Incyte was 72.80. The lowest was 4.21. And the median was 11.43.


Incyte  (NAS:INCY) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Incyte's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=119.52/16.83
=7.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Incyte was 72.80. The lowest was 4.21. And the median was 11.43.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Incyte Cyclically Adjusted Revenue per Share Related Terms


Incyte Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Incyte's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incyte Cyclically Adjusted Revenue per Share Chart

Incyte Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.61 9.34 10.98 12.93 15.30

Incyte Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.12 14.75 15.30 16.02 16.83

INCY vs INSM, BNTX, ROIV: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Incyte's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incyte Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incyte's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Incyte's Cyclically Adjusted PS Ratio falls into.


INCY
87GF Score
Incyte Corp INCY
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Incyte Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Incyte's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=8.04/333.9520*333.9520
=8.040

Current CPI (Jun. 2026) = 333.9520.

Incyte Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.387 241.428 1.919
201612 1.672 241.432 2.313
201703 1.967 243.801 2.694
201706 1.591 244.955 2.169
201709 1.795 246.819 2.429
201712 2.104 246.524 2.850
201803 1.806 249.554 2.417
201806 2.424 251.989 3.212
201809 2.082 252.439 2.754
201812 2.446 251.233 3.251
201903 2.294 254.202 3.014
201906 2.437 256.143 3.177
201909 2.533 256.759 3.295
201912 2.652 256.974 3.446
202003 2.623 258.115 3.394
202006 3.121 257.797 4.043
202009 2.837 260.280 3.640
202012 3.601 260.474 4.617
202103 2.726 264.877 3.437
202106 3.175 271.696 3.903
202109 3.658 274.310 4.453
202112 3.887 278.802 4.656
202203 3.289 287.504 3.820
202206 4.075 296.311 4.593
202209 3.673 296.808 4.133
202212 4.120 296.797 4.636
202303 3.585 301.836 3.966
202306 4.231 305.109 4.631
202309 4.063 307.789 4.408
202312 4.475 306.746 4.872
202403 3.877 312.332 4.145
202406 4.784 314.175 5.085
202409 5.810 315.301 6.154
202412 5.699 315.605 6.030
202503 5.312 319.799 5.547
202506 6.116 322.561 6.332
202509 6.781 324.800 6.972
202512 7.365 324.054 7.590
202603 6.153 330.213 6.223
202606 8.040 333.952 8.040

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $16.83 mean?
Incyte (INCY) has a Cyclically Adjusted Revenue per Share of $16.83 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Incyte and its competitors.
Is Incyte's Cyclically Adjusted Revenue per Share too high?
Incyte's current Cyclically Adjusted Revenue per Share is $16.83. Overall, Incyte has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Incyte's Cyclically Adjusted Revenue per Share compare to INSM and BNTX?
Incyte's Cyclically Adjusted Revenue per Share of $16.83 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Incyte and its competitors. Incyte's current Cyclically Adjusted Revenue per Share is $16.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Based on GuruFocus' analysis, Incyte (INCY) is currently considered Modestly Overvalued. The stock's GF Value™ is $105.33, compared to a current price of $119.52 — trading 13.5% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $16.83. Incyte's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Incyte (INCY), the current Cyclically Adjusted Revenue per Share is $16.83 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Incyte (INCY) Overvalued in 2026?

Based on GuruFocus' analysis, Incyte stock appears to be overvalued. The current stock price of $119.52 is trading 13.5% above its estimated GF Value™ of $105.33. GuruFocus considers Incyte to be Modestly Overvalued.

Key valuation signals for INCY:

  • Cyclically Adjusted Revenue per Share: $16.83
  • GF Value™: $105.33 vs. price of $119.52 (13.5% above fair value)
  • GF Score™: 87/100 with 4 warning signs

No single metric tells the full story. See the INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Incyte Business Description

Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
87GF Score

Get the complete analysis for INCY

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$119.52
Price
$105.33
GF Value